Pfizer Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Pfizer has entered into an exclusive Supply and Marketing Agreement with Cipla for marketing and distribution of four brands of the Company, viz., Corex Dx, Corex LS, Dolonex, and Neksium for an initial period of 5 years.

Powered by Capital Market - Live News

On a standalone basis, net sales stood at Rs 642.34 crore, rising 9.1% year-on-year from Rs 588.59 crore in Q2 FY25 and 6.5% sequentially from Rs 603.05 crore in Q1 FY26.

Net profit (PAT) rose 19.4% YoY to Rs 189.02 crore, compared with Rs 158.35 crore in Q2 FY25, as current tax expense increased 9.4% to Rs 65.49 crore. Sequentially, PAT was down 1.4% from Rs 191.75 crore in Q1 FY26.

Profit before tax (PBT) climbed 18.7% YoY to Rs 255.37 crore, though slightly lower by 1.6% QoQ.

Total expenditure inched up 3.3% YoY and 4.9% QoQ to Rs 412.41 crore. Raw material costs declined 8.7% YoY to Rs 70 crore, while employee expenses fell 6% YoY to Rs 94.67 crore. Depreciation stood at Rs 14.28 crore, down 4.74% year-on-year, while interest expenses were steady at Rs 2.13 crore.

Net cash flow from operating activities stood at Rs 599.47 crore in H1 FY26, as against a cash flow of Rs 349.43 crore in H1 FY25.

Pfizer is engaged in manufacturing, marketing, trading and export of pharmaceutical products.

Powered by Capital Market - Live News

Net profit of Pfizer rose 19.37% to Rs 189.02 crore in the quarter ended September 2025 as against Rs 158.35 crore during the previous quarter ended September 2024. Sales rose 9.13% to Rs 642.34 crore in the quarter ended September 2025 as against Rs 588.59 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Pfizer will hold a meeting of the Board of Directors of the Company on 12 November 2025.

Powered by Capital Market - Live News